Savient Pharma (SVNT) Tops Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts SVNT Hot Sheet
Join SI Premium – FREE
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) reported Q3 loss of ($0.39), $0.01 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $2.58 million versus the consensus estimate of $3.17 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
- Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
